Racura Oncology Ltd

Racura Oncology Ltd, formerly Race Oncology Limited, is an Australia-based Phase III clinical biopharmaceutical company with a focus on cancer care. The Company's lead asset, RCDS1 (E,E-bisantrene), is a small molecule anticancer agent that primarily functions via G4-DNA and RNA binding, leading to potent inhibition of the important cancer growth regulator MYC. RCDS1 has demonstrated therapeutic activity in cancer patients with a well characterized safety profile. The Company is advancing a formulation of RCDS1 (RC220) to address the high unmet needs of patients across multiple oncology indications, with Phase III clinical programs in acute myeloid leukemia (AML), a Phase I a/b program in mutant epidermal growth factor receptor non-small cell lung cancer (EGFRm NSCLC), and a Phase I a/b program in combination with the anthracycline doxorubicin, where the Company is focused on delivering both cardioprotection and enhanced anticancer activity for solid tumor patients.